These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8478056)

  • 1. Safety, stability, and efficacy of noncapsulated mutants of Actinobacillus pleuropneumoniae for use in live vaccines.
    Inzana TJ; Todd J; Veit HP
    Infect Immun; 1993 May; 61(5):1682-6. PubMed ID: 8478056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment of transmission of capsule-deficient, recombinant Actinobacillus pleuropneumoniae.
    Inzana TJ; Glindemann G; Fenwick B; Longstreth J; Ward D
    Vet Microbiol; 2004 Nov; 104(1-2):63-71. PubMed ID: 15530740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction and immunogenicity of an attenuated mutant of Actinobacillus pleuropneumoniae by insertional inactivation of apxIC].
    Xu FZ; Shi AH; Chen XL; Yang B; Wang JL
    Wei Sheng Wu Xue Bao; 2007 Oct; 47(5):923-7. PubMed ID: 18062275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of the znuA virulence factor attenuates Actinobacillus pleuropneumoniae and confers protection against homologous or heterologous strain challenge.
    Yuan F; Liao Y; You W; Liu Z; Tan Y; Zheng C; BinWang ; Zhou D; Tian Y; Bei W
    Vet Microbiol; 2014 Dec; 174(3-4):531-539. PubMed ID: 25465668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuated Actinobacillus pleuropneumoniae double-deletion mutant S-8∆clpP/apxIIC confers protection against homologous or heterologous strain challenge.
    Xie F; Li G; Zhou L; Zhang Y; Cui N; Liu S; Wang C
    BMC Vet Res; 2017 Jan; 13(1):14. PubMed ID: 28061786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine.
    Tonpitak W; Baltes N; Hennig-Pauka I; Gerlach GF
    Infect Immun; 2002 Dec; 70(12):7120-5. PubMed ID: 12438394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New trends in innovative vaccine development against Actinobacillus pleuropneumoniae.
    Loera-Muro A; Angulo C
    Vet Microbiol; 2018 Apr; 217():66-75. PubMed ID: 29615259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The live attenuated Actinobacillus pleuropneumoniae triple-deletion mutant ΔapxIC ΔapxIIC ΔapxIV-ORF1 strain, SLW05, Immunizes pigs against lethal challenge with Haemophilus parasuis.
    Fu S; Ou J; Zhang M; Xu J; Liu H; Liu J; Yuan F; Chen H; Bei W
    Clin Vaccine Immunol; 2013 Feb; 20(2):134-9. PubMed ID: 23220998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the protective efficacy of Actinobacillus pleuropneumoniae serotype 1 detoxified lipopolysaccharides or O-polysaccharide-protein conjugate in pigs.
    Rioux S; Girard C; Dubreuil JD; Jacques M
    Res Vet Sci; 1998; 65(2):165-7. PubMed ID: 9839897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
    Maas A; Meens J; Baltes N; Hennig-Pauka I; Gerlach GF
    Vaccine; 2006 Nov; 24(49-50):7226-37. PubMed ID: 17027123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of secreted virulence factors in Actinobacillus pleuropneumoniae bacterin preparation: a comparison.
    Fedorka-Cray PJ; Stine DL; Greenwald JM; Gray JT; Huether MJ; Anderson GA
    Vet Microbiol; 1993 Oct; 37(1-2):85-100. PubMed ID: 8296454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
    Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
    Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral immunization of pigs with viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces pulmonary and systemic antibodies and protects against homologous aerosol challenge.
    Hensel A; Stockhofe-Zurwieden N; Petzoldt K; Lubitz W
    Infect Immun; 1995 Aug; 63(8):3048-53. PubMed ID: 7622229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-protection between Actinobacillus pleuropneumoniae biotypes-serotypes in pigs.
    Haesebrouk F; Van de Kerkhof A; Dom P; Chiers K; Ducatelle R
    Vet Microbiol; 1996 Oct; 52(3-4):277-84. PubMed ID: 8972053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective efficacy of an affinity-purified hemolysin vaccine against experimental swine pleuropneumonia.
    Haga Y; Ogino S; Ohashi S; Ajito T; Hashimoto K; Sawada T
    J Vet Med Sci; 1997 Feb; 59(2):115-20. PubMed ID: 9070983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genetically-defined riboflavin auxotroph of Actinobacillus pleuropneumoniae as a live attenuated vaccine.
    Fuller TE; Thacker BJ; Duran CO; Mulks MH
    Vaccine; 2000 Jun; 18(25):2867-77. PubMed ID: 10812230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs.
    Wu HC; Yeh PH; Hsueh KJ; Yang WJ; Chu CY
    J Appl Microbiol; 2018 Jun; 124(6):1366-1376. PubMed ID: 29431246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state.
    Hensel A; Huter V; Katinger A; Raza P; Strnistschie C; Roesler U; Brand E; Lubitz W
    Vaccine; 2000 Jul; 18(26):2945-55. PubMed ID: 10825595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Construction and characterization of Actinobacillus pleuropneumoniae serovar 7 live attenuated vaccine strain co-expressing ApxIA].
    Liu J; Chen Y; Hu L; Bei W; Chen H
    Sheng Wu Gong Cheng Xue Bao; 2010 Mar; 26(3):305-10. PubMed ID: 20518341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs.
    Bei W; He Q; Zhou R; Yan L; Huang H; Chen H
    Vet Microbiol; 2007 Nov; 125(1-2):120-7. PubMed ID: 17580102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.